A Study to Determine the Effect of CYP3A Inhibition on the Pharmacokinetics of LY2623091 and the Effect of LY2623091 on the Pharmacokinetics of CYP3A Substrates in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 12 Mar 2016
At a glance
- Drugs LY 2623091 (Primary) ; Diltiazem; Itraconazole; Simvastatin; Tadalafil
- Indications Essential hypertension
- Focus Pharmacokinetics
- Sponsors Eli Lilly
- 12 Mar 2016 Pharmacokinetic results (n=32) of LY-2623091 with itraconazole and diltiazem were presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
- 16 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 11 Mar 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.